Ibrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survival

Abstract

Atrial fibrillation is a well recognized side effects of several drugs. However it is ignored since most studies have failed to show that it impacts survival adversely. This is not the case with ibrutinib, especially amongst patients with pre-existing cardiac morbidities. In this article, we provide practical consensus guidelines for cancer patients being commenced on therapy with ibrutinib.

Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification

“…While CVSEs with second generation BTK inhibitors are less, 2-9% continue to experience arrhythmias, while comparable rates of hypertension between BTK inhibitors suggest a class effect [ 4 ]. Notably, development of BTK-inhibitor-related CVSEs are associated with worse long-term CV and overall survival [ 5 ].…”